Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/20/2019
Start Date:September 8, 2017
End Date:December 29, 2020
Contact:Novartis Pharmaceuticals
Email:Novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

This is a Phase Ib, multi-center, open-label study to characterize the safety, tolerability,
pharmacokinetics, pharmacodynamics and preliminary antitumor activity of MIW815(ADU-S100) in
combination with the PD-1 checkpoint inhibitor PDR001. Two different schedules will be
explored in two dose escalation groups in accessible cutaneous or subcutaneous lesions, as
well as an optional dose confirmation group exploring intratumoral injection of viscerally
located lesions.

Group A will include patients with accessible solid tumors and lymphomas. This group will
receive a fixed dose of PDR001 i.v. on day 1 of every 28 day cycle and intratumoral
injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle. Group B will
include patients with accessible solid tumors and lymphomas. This group will receive a fixed
dose of PDR001 i.v. on day 1 of every cycle and an intratumoral injection of MIW815
(ADU-S100) on day 1 of every cycle.

Once the dose and dose schedule has been confirmed, the dose expansion part of the study will
open. The main purpose of the expansion part is to further assess the safety and
tolerability, as well as preliminary anti-tumor activity, of the study treatment at the
maximum tolerated dose and/or recommended dose for expansion. .

Inclusion Criteria:

ECOG ≤ 1 Willing to undergo tumor biopsies from injected and distal lesions

Must have two biopsy accessible lesions:

Exclusion Criteria:

Symptomatic or untreated leptomeningeal disease. Presence of symptomatic central nervous
system metastases Impaired cardiac function or clinically significant cardiac disease
Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or
resolved childhood asthma/atopy.

Active infection requiring systemic antibiotic therapy. Known history of human
immunodeficiency virus infection. Active Epstein-Barr virus, hepatitis B virus or hepatitis
C virus Malignant disease, other than that being treated in this study
We found this trial at
4
sites
Melbourne, Victoria
?
mi
from
Melbourne,
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Jason Luke
Phone: 773-702-1835
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Funda Meric-Bernstam
Phone: +1 713 745 4453
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials